Cargando…

Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

SIMPLE SUMMARY: High lymphocytic infiltration (TILs) seem to reflect favorable host antitumor immune responses. In breast cancer, the variation of TILs before and after neoadjuvant chemotherapy (NAC) according to BRCA status has been poorly described. Little data is available on their value after tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grandal, Beatriz, Evrevin, Clémence, Laas, Enora, Jardin, Isabelle, Rozette, Sonia, Laot, Lucie, Dumas, Elise, Coussy, Florence, Pierga, Jean-Yves, Brain, Etienne, Saule, Claire, Stoppa-Lyonnet, Dominique, Frank, Sophie, Sénéchal, Claire, Lae, Marick, De Croze, Diane, Bataillon, Guillaume, Guerin, Julien, Reyal, Fabien, Hamy, Anne-Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764707/ https://www.ncbi.nlm.nih.gov/pubmed/33302444 http://dx.doi.org/10.3390/cancers12123681

Ejemplares similares

No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis
por: Simon, Vanille, et al.
Publicado: (2020)

The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes
por: Laot, Lucie, et al.
Publicado: (2021)

Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy
por: Hamy, Anne-Sophie, et al.
Publicado: (2020)

HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens
por: Laas, Enora, et al.
Publicado: (2021)

Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore
por: Laas, Enora, et al.
Publicado: (2021)

PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy
por: Grandal, Beatriz, et al.
Publicado: (2021)

The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer
por: Labrosse, Julie, et al.
Publicado: (2021)

Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis
por: Labrosse, Julie, et al.
Publicado: (2020)

No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NAC
por: Grandal, Beatriz, et al.
Publicado: (2022)

Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer
por: Hamy, Anne-Sophie, et al.
Publicado: (2019)

Time to Pregnancy, Obstetrical and Neonatal Outcomes after Breast Cancer: A Study from the Maternity Network for Young Breast Cancer Patients
por: Labrosse, Julie, et al.
Publicado: (2021)

Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns
por: Gougis, Paul, et al.
Publicado: (2023)

The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS)
por: Dumas, Elise, et al.
Publicado: (2022)

Breast Cancer (BC) Is a Window of Opportunity for Smoking Cessation: Results of a Retrospective Analysis of 1234 BC Survivors in Follow-Up Consultation
por: Nicolas, Marion, et al.
Publicado: (2021)

Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach
por: Laas, Enora, et al.
Publicado: (2019)

Interactive exploration of a global clinical network from a large breast cancer cohort
por: Sella, Nadir, et al.
Publicado: (2022)

Evolution of synchronous female bilateral breast cancers and response to treatment
por: Hamy, Anne-Sophie, et al.
Publicado: (2023)

Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy
por: Hours, Alice, et al.
Publicado: (2021)

Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
por: Gosset, Marie, et al.
Publicado: (2016)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy, Anne-Sophie, et al.
Publicado: (2018)

Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)
por: Sebbag, Clara, et al.
Publicado: (2022)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy-Petit, Anne-Sophie, et al.
Publicado: (2016)

Effects of gender and socio-environmental factors on health-care access in oncology: a comprehensive, nationwide study in France
por: Jochum, Floriane, et al.
Publicado: (2023)

Impact of the Area of Residence of Ovarian Cancer Patients on Overall Survival
por: Jochum, Floriane, et al.
Publicado: (2022)

Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial
por: Delrieu, Lidia, et al.
Publicado: (2022)

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
por: Hamy, Anne-Sophie, et al.
Publicado: (2016)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast
por: Bièche, Ivan, et al.
Publicado: (2021)

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application
por: Laas, Enora, et al.
Publicado: (2016)

Sentinel Lymph Node Biopsy in Uterine Cancer: Time for a Modern Approach
por: Laas, Enora, et al.
Publicado: (2023)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Patterns of Sequelae in Women with a History of Localized Breast Cancer: Results from the French VICAN Survey
por: Delrieu, Lidia, et al.
Publicado: (2021)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

Fysikkpris til Fanamann
Publicado: (1981)

Petabytes til folket
Publicado: (2005)

Goldilocks and the three TILs
por: Dada, Hannah, et al.
Publicado: (2022)

Towards next‐generation TIL therapy: TILs enriched in neoepitope‐specific T cells
por: Arnaud, Marion, et al.
Publicado: (2023)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
por: Rossi, L, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9915kmf6jdq5dccmajnc7paiu2